Fujian Cancer Hospital (Fujian Cancer Institute, Fujian Cancer Prevention and Treatment Center)

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.

Phase 2

Recruiting

Conditions: Ovarian Neoplasms
Ovarian Diseases

Interventions: Drug: Adebrelimab
Drug: Fuzuloparib

First Posted Date: 2023-03-03

Last Posted Date: 2024-02-06

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 37

Registration Number: NCT05753826

Locations: 🇨🇳
Fujian Cancer Hospital, Fujian, China

Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer

Phase 2

Not yet recruiting

Conditions: Gastric Cancer

Interventions: Drug: Tislelizumab
Drug: 5Fu
Drug: Paclitaxel injection

First Posted Date: 2023-03-02

Last Posted Date: 2023-06-22

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 39

Registration Number: NCT05751265

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Phase 2

Recruiting

Conditions: Immunotherapy Gastrict Cancer

Interventions: Drug: Tislelizumab
Drug: apatinib
Drug: oxaliplatin
Drug: S-1

First Posted Date: 2023-01-26

Last Posted Date: 2024-05-01

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 130

Registration Number: NCT05699655

Locations: 🇨🇳
Fujian cancer hospital, Fuzhou, Fujian, China

Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma

Phase 2

Not yet recruiting

Conditions: Lung Adenocarcinoma
Stage IV Non-small Cell Lung Cancer
PD-1 Inhibitor
VEGF

Interventions: Drug: Serplulimab and Bevacizumab injection

First Posted Date: 2023-01-09

Last Posted Date: 2023-01-09

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 50

Registration Number: NCT05675033

Almonertinib Plus Metronomic Oral Vinorelbine

Not yet recruiting

Conditions: EGFR
Third-generation TKI
NSCLC

Interventions: Drug: Almonertinib and metronomic oral vinorelbine

First Posted Date: 2022-12-23

Last Posted Date: 2022-12-23

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 40

Registration Number: NCT05663177

Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma

Phase 2

Not yet recruiting

Conditions: Malignant Melanoma
Liver Metastases

Interventions: Drug: Recombinant Human Adenovirus Type 5 Injection,Camrelizumab,Nab-paclitaxel

First Posted Date: 2022-12-23

Last Posted Date: 2023-02-08

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 30

Registration Number: NCT05664139

TIL Cells for the Treatment of the Advanced Solid Tumors Patients

Early Phase 1

Not yet recruiting

Conditions: Solid Tumor

Interventions: Biological: Tumor Infiltrating Lymphocytes
Drug: Fludarabine
Drug: Cyclophosphamide Capsules
Drug: IL-2

First Posted Date: 2022-12-14

Last Posted Date: 2022-12-14

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 42

Registration Number: NCT05649618

TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors

Early Phase 1

Not yet recruiting

Conditions: Solid Tumors

Interventions: Biological: TCR-T cells
Drug: Fludarabine
Drug: Cyclophosphamide Capsules
Drug: Albumin-bound paclitaxel
Drug: IL-2

First Posted Date: 2022-12-13

Last Posted Date: 2022-12-13

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 30

Registration Number: NCT05648994

The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy

Phase 2

Not yet recruiting

Conditions: Rectal Cancer

Interventions: Drug: PD-1
Radiation: SCRT
Drug: Bevacizumab
Drug: Oxaliplatin
Drug: Calcium folinate
Drug: 5-fluorouracil

First Posted Date: 2022-12-07

Last Posted Date: 2022-12-07

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 30

Registration Number: NCT05640726

Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer

Phase 2

Not yet recruiting

Conditions: Esophageal Cancer

Interventions: Drug: Tislelizumab
Radiation: Radiation
Drug: Paclitaxel

First Posted Date: 2022-11-28

Last Posted Date: 2024-08-13

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 130

Registration Number: NCT05628610

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy